CE: Entresto: An Overview for Pharmacists
David Comshaw
Abstract
Entresto is a new drug that was developed for NYHA stage II heart failure. It was evaluated through the PARAMOUNT-HF and PARADIGM trials and showed some benefits to patients suffering from heart failure. There are many products that are approved for the treatment of heart failure to either decrease morbidity/mortality or provide symptom relief. It is a serious disease state and provides pharmacists with an opportunity to make appropriate recommendations in order to benefit patients. This review will discuss different characteristics of Entresto and some of the evidence associated with its use. 
Full Text
Vol1Article3.pdf
File Size: 445 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH